The approved ANDA is therapeutically equivalent to the reference listed drug product (RLD), Xarelto Tablets, 2.5 mg, 10 mg, ...

Alembic reported a 14% increase in its consolidated net profit, reaching Rs 24 crore in Q4 of FY25. The company's revenue ...

Alembic Pharmaceuticals (Alembic) today announced that it has received final approval from the US Food & Drug Administration (USFDA) for its Abbreviated New Drug Application (ANDA) Rivaroxaban Tablets ...

Alembic Pharmaceuticals experienced a 12.1% dip in Q4 net profit, reaching Rs 156.63 crore, despite a 16.7% surge in revenue ...

Quarterly Net Profit at Rs. 156.89 crore in March 2025 down 11.96% from Rs. 178.21 crore in March 2024. EBITDA stands at Rs.

Alembic Pharmaceuticals' Q4FY25 net profit declines 12% YoY to Rs 157 crore while revenue rises 17% to Rs 1,770 crore; India ...

Quarterly Net Profit at Rs. 75.34 crore in March 2025 down 62.68% from Rs. 201.87 crore in March 2024. EBITDA stands at Rs.

Alembic Pharmaceuticals reported an 11.8% drop in Q4 net profit even as revenue rose 17% year-on-year. The Board has ...

Indian drugmaker Alembic Pharmaceuticals reported a 12% fall in fourth-quarter profit on Tuesday, hurt by a deferred tax expense that offset the impact of strong sales in its key U.S. and domestic ...

The P/B ratio shows how a stock's market price compares to its book value. It helps gauge whether a stock is undervalued or overvalued relative to its net assets.

Alembic Pharmaceuticals has received USFDA approval to market generic Ticagrelor Tablets, a medication for preventing heart attack and stroke. The drug is therapeutically equivalent to AstraZeneca's ...

The Sensex fell 156 points to close at 80,641, while the Nifty ended 82 points lower at 24,380. The pressure was far more ...